Arteriosclerosis, Vol 8, 68-72, Copyright © 1988 by American Heart Association

ARTICLES

Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus

J Auwerx, R Bouillon, D Collen and J Geboers
Laboratory for Experimental Medicine, University of Leuven, Belgium.

Parameters of fibrinolysis, including euglobulin fibrinolytic activity, tissue-type plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PA-inhibitor) activity, and plasmin-alpha 2-antiplasmin complex (PAP) were studied in 62 patients (35 women and 27 men; ages 53 +/- 16 years) with either insulin-dependent (IDDM) or noninsulin- dependent (NIDDM) diabetes mellitus. Compared to a control group of similar age (n = 57), the diabetic patients had a significantly lower mean euglobulin fibrinolytic activity (1.2 +/- 0.7 vs. 1.7 +/- 1.1 ng/ml, p less than 0.01) but significantly higher mean t-PA antigen (15.7 +/- 8.4 vs. 6.6 +/- 2.9 ng/ml, p less than 0.001) and PA- inhibitor activity (2.6 +/- 1.3 vs. 1.5 +/- 0.7 IU/ml, p less than 0.001) levels. Significant univariate correlations were observed between PA-inhibitor activity and age (r = 0.32, p less than 0.05), diastolic blood pressure (r = 0.42, p less than 0.01) and euglobulin fibrinolytic activity (r = -0.40, p less than 0.01). In multivariate analysis, only body mass index (positively) and euglobulin fibrinolytic activity (negatively) remained significantly related to PA-inhibitor activity in the total diabetic population as well as in the NIDDM group. The only parameter in the IDDM group significantly related to PA- inhibitor activity was diastolic blood pressure. These results suggest that PA-inhibitor plays a role in the regulation of fibrinolysis in diabetes patients and that factors like obesity and hypertension may be related to reduced fibrinolysis via PA-inhibitor levels.

This article has been cited by other articles:

				Y. Huang, W. A. Border, L. Yu, J. Zhang, D. A. Lawrence, and N. A. Noble A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2008; 19(2): 329 - 338. [Abstract] [Full Text] [PDF]

				J. A.S. Muldowney III, J. R. Stringham, S. E. Levy, L. A. Gleaves, M. Eren, R. N. Piana, and D. E. Vaughan Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 Expression: A Potential Prothrombotic Mechanism of Drug-Eluting Stents Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 400 - 406. [Abstract] [Full Text] [PDF]

				H. Fujita, M. Kang, M. Eren, L. A. Gleaves, D. E. Vaughan, and T. Kume Foxc2 Is a Common Mediator of Insulin and Transforming Growth Factor {beta} Signaling to Regulate Plasminogen Activator Inhibitor Type I Gene Expression Circ. Res., March 17, 2006; 98(5): 626 - 634. [Abstract] [Full Text] [PDF]

				M. Ribo, C. Molina, J. Montaner, M. Rubiera, R. Delgado-Mederos, J. F. Arenillas, M. Quintana, and J. Alvarez-Sabin Acute Hyperglycemia State Is Associated With Lower tPA-Induced Recanalization Rates in Stroke Patients Stroke, August 1, 2005; 36(8): 1705 - 1709. [Abstract] [Full Text] [PDF]

				Y. Uchida, K.-i. Ohba, T. Yoshioka, K. Irie, T. Muraki, and Y. Maru Cellular Carbonyl Stress Enhances the Expression of Plasminogen Activator Inhibitor-1 in Rat White Adipocytes via Reactive Oxygen Species-dependent Pathway J. Biol. Chem., February 6, 2004; 279(6): 4075 - 4083. [Abstract] [Full Text] [PDF]

				B. E. Sobel, R. Frye, and K. M. Detre Burgeoning Dilemmas in the Management of Diabetes and Cardiovascular Disease: Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Circulation, February 4, 2003; 107(4): 636 - 642. [Abstract] [Full Text] [PDF]

				S. Devaraj, A. V. C. Chan Jr., and I. Jialal {alpha}-Tocopherol Supplementation Decreases Plasminogen Activator Inhibitor-1 and P-Selectin Levels in Type 2 Diabetic Patients Diabetes Care, March 1, 2002; 25(3): 524 - 529. [Abstract] [Full Text] [PDF]

				C. Zoccali, F. Mallamaci, G. Tripepi, F. A. Benedetto, S. Cutrupi, S. Parlongo, L. S. Malatino, G. Bonanno, G. Seminara, F. Rapisarda, et al. Adiponectin, Metabolic Risk Factors, and Cardiovascular Events among Patients with End-Stage Renal Disease J. Am. Soc. Nephrol., January 1, 2002; 13(1): 134 - 141. [Abstract] [Full Text] [PDF]

				M. S. Sabatine and E. Braunwald Will Diabetes Save the Platelet Blockers? Circulation, December 4, 2001; 104(23): 2759 - 2761. [Full Text] [PDF]

				N. YEVDOKIMOVA, N. A. WAHAB, and R. M. MASON Thrombospondin-1 Is the Key Activator of TGF-{beta}1 in Human Mesangial Cells Exposed to High Glucose J. Am. Soc. Nephrol., April 1, 2001; 12(4): 703 - 712. [Abstract] [Full Text] [PDF]

				J. Calles-Escandon and M. Cipolla Diabetes and Endothelial Dysfunction: A Clinical Perspective Endocr. Rev., February 1, 2001; 22(1): 36 - 52. [Abstract] [Full Text]

				Y. Chen, J. J. Billadello, and D. J. Schneider Identification and Localization of a Fatty Acid Response Region in the Human Plasminogen Activator Inhibitor-1 Gene Arterioscler. Thromb. Vasc. Biol., December 1, 2000; 20(12): 2696 - 2701. [Abstract] [Full Text] [PDF]

				M. H. Poczatek, C. Hugo, V. Darley-Usmar, and J. E. Murphy-Ullrich Glucose Stimulation of Transforming Growth Factor-{beta} Bioactivity in Mesangial Cells Is Mediated by Thrombospondin-1 Am. J. Pathol., October 1, 2000; 157(4): 1353 - 1363. [Abstract] [Full Text] [PDF]

				M. B. Grant, P. E. Spoerri, D. W. Player, D. M. Bush, E. A. Ellis, S. Caballero, and W. G. Robison Plasminogen Activator Inhibitor (PAI)-1 Overexpression in Retinal Microvessels of PAI-1 Transgenic Mice Invest. Ophthalmol. Vis. Sci., July 1, 2000; 41(8): 2296 - 2302. [Abstract] [Full Text]

				H. P. Kohler and P. J. Grant Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease N. Engl. J. Med., June 15, 2000; 342(24): 1792 - 1801. [Full Text] [PDF]

				K. Hotta, T. Funahashi, Y. Arita, M. Takahashi, M. Matsuda, Y. Okamoto, H. Iwahashi, H. Kuriyama, N. Ouchi, K. Maeda, et al. Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1595 - 1599. [Abstract] [Full Text] [PDF]

				L. Tarnow, C. D. A. Stehouwer, J. J. Emeis, O. Poirier, F. Cambien, B. V. Hansen, and H.-H. Parving Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy Nephrol. Dial. Transplant., May 1, 2000; 15(5): 625 - 630. [Abstract] [Full Text] [PDF]

				B. E. Sobel Increased Plasminogen Activator Inhibitor-1 and Vasculopathy : A Reconcilable Paradox Circulation, May 18, 1999; 99(19): 2496 - 2498. [Full Text] [PDF]

				H. E. Grenett, R. L. Benza, G. M. Fless, X.-N. Li, G. C. Davis, and F. M. Booyse Genotype-Specific Transcriptional Regulation of PAI-1 Gene by Insulin, Hypertriglyceridemic VLDL, and Lp(a) in Transfected, Cultured Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1803 - 1809. [Abstract] [Full Text] [PDF]

				D. J. Schneider, P. M. Absher, and M. A. Ricci Dependence of Augmentation of Arterial Endothelial Cell Expression of Plasminogen Activator Inhibitor Type 1 by Insulin on Soluble Factors Released From Vascular Smooth Muscle Cells Circulation, November 4, 1997; 96(9): 2868 - 2876. [Abstract] [Full Text]

				Y. Hong, N. L. Pedersen, N. Egberg, and U. de Faire Moderate Genetic Influences on Plasma Levels of Plasminogen Activator Inhibitor-1 and Evidence of Genetic and Environmental Influences Shared by Plasminogen Activator Inhibitor-1, Triglycerides, and Body Mass Index Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2776 - 2782. [Abstract] [Full Text]

				X.-N. Li, H. E. Grenett, R. L. Benza, S. Demissie, S. L. Brown, E. M. Tabengwa, S. H. Gianturco, W. A. Bradley, G. M. Fless, and F. M. Booyse Genotype-Specific Transcriptional Regulation of PAI-1 Expression by Hypertriglyceridemic VLDL and Lp(a) in Cultured Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3215 - 3223. [Abstract] [Full Text]

				A. Aviv and H. Aviv Reflections on Telomeres, Growth, Aging, and Essential Hypertension Hypertension, May 1, 1997; 29(5): 1067 - 1072. [Abstract] [Full Text]

				B. E. Sobel Potentiation of Vasculopathy by Insulin : Implications From an NHLBI Clinical Alert Circulation, May 1, 1996; 93(9): 1613 - 1615. [Full Text]

				M. Margaglione, G. DiMinno, E. Grandone, E. Celentano, G. Vecchione, G. Cappucci, M. Grilli, F. P. Mancini, A. Postiglione, S. Panico, et al. Plasma Lipoprotein(a) Levels in Subjects Attending a Metabolic Ward : Discrimination Between Individuals With and Without a History of IschemicStroke Arterioscler. Thromb. Vasc. Biol., January 1, 1996; 16(1): 120 - 128. [Abstract] [Full Text]

				P. Rubba, G. Leccia, F. Faccenda, B. De Simone, L. Carbone, P. Pauciullo, O. Vaccaro, and M. Mancini Diabetes Mellitus and Localizations of Obliterating Arterial Disease of the Lower Limbs Angiology, April 1, 1991; 42(4): 296 - 301. [Abstract] [PDF]